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Abstract
Background: 2-methylbutyryl-CoA dehydrogenase deficiency or short/branched chain acyl-CoA
dehydrogenase deficiency (SBCADD) is caused by a defect in the degradation pathway of the amino
acid L-isoleucine.
Methods: We report a four-year-old mentally retarded Somali boy with autism and a history of
seizures, who was found to excrete increased amounts of 2-methylbutyryl glycine in the urine. The
SBCAD gene was examined with sequence analysis. His development was assessed with
psychometric testing before and after a trial with low protein diet.
Results: We found homozygosity for A > G changing the +3 position of intron 3 (c.303+3A > G)
in the SBCAD gene. Psychometric testing showed moderate mental retardation and behavioral
scores within the autistic spectrum. No beneficial effect was detected after 5 months with a low
protein diet.
Conclusion: This mutation was also found in two previously reported cases with SBCADD, both
originating from Somalia and Eritrea, indicating that it is relatively prevalent in this population.
Autism has not previously been described with mutations in this gene, thus expanding the clinical
spectrum of SBCADD.
Background
2-methylbutyryl-CoA dehydrogenase deficiency, also
known as short/branched chain acyl- CoA dehydrogenase
deficiency (SBCADD) (OMIM 61006), is a recently
described autosomal recessive disorder caused by a defect
in the degradation pathway of L- isoleucine leading to
increased urinary excretion of 2-methylbutyryl glycine
[1,2]. The enzymatic defect results from disruption of the
SBCAD gene (ACADSB) [3]. The clinical consequences of
mutations in this gene are unclear as patients can be
divided into two categories. The first category consists of
infants detected by newborn screening programmes.
These infants are treated with diet and remain without
clinical symptoms. In the second category affected
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patients were diagnosed because they presented clinically
with seizures and psychomotor delay and had increased
urinary excretion of 2-methylbutyryl glycine [4,5]. The
brain, where isoleucine is oxidized as fuel, is primarily
affected in these patients. We report an autistic and men-
tally retarded boy with 2-methyl butyryl glycinuria and
homozygosity for a deleterious mutation in ACADSB. He
is the first to be described with SBCADD and autism.
Case presentation
The patient was a four-year-old boy who was the third
child of healthy Somali parents. They belong to the same
tribe, but are probably not closely related. After an une-
ventful pregnancy, he was delivered at term without com-
plications in Somalia in 2001. Birth weight, length, head
circumference and Apgar scores are not known, but the
mother described him as a healthy and normal infant
until he was 5 months old. From this age he started to
have seizure-like movements, which according to the
mother's description, could have been myoclonic epilepsy
or infantile spasms. At first, the seizures appeared at night,
but soon they also occurred during the day, with increas-
ing frequency and duration. The seizures stopped at 8
months after he was examined in a local hospital and put
on antiepileptic drug therapy. Despite becoming seizure
free, the mother described him as becoming markedly less
responsive and alert.
Growth and motor development were normal for his age.
He crawled at the age of 9 months and walked unsup-
ported at the age of 12 months. Speech development was
significantly delayed. The family moved to Norway when
he was 1 1/2 years old. Although he could say some words
at 2 years of age, verbal language skills improved only lit-
tle after this age. At the age of 4 years he entered a day-care
centre for autistic children, as it was observed that he had
limited communication and social skills, gave poor eye
contact and displayed a repetitive pattern of behavior.
Clinical examination at 5 years did not reveal any dysmor-
phic features. His muscle tone and strength and coordina-
tion and deep tendon reflexes were normal without signs
of peripheral sensory deficit. His height and weight corre-
sponded to the 25th centiles, and his head circumference
was at the 75th centile. Eye examination with fundoscopy,
hearing test, electroencephalography (EEG), echocardiog-
raphy of the heart and magnetic resonance imaging of the
brain were normal. Blood glucose, urea, creatinine, and
liver transaminases were normal. Chromosome analysis
showed a normal 46, XY karyotype. A Southern blot test
for Angelman syndrome was negative.
Since the time of the diagnosis of SBCADD our patient
was on a trial with protein restricted diet (1 g protein/kg/
day) for 5 months. The diet was reasonably well adhered
to. He was tested by a psychologist using standard tests
before and after 5 months of protein restriction treatment.
No observable improvement was demonstrated during
the period.
Neuropsychological examination
When examined with ADOS-G (Autism Diagnostic Obser-
vation Schedule-Generic), he obtained a score of 13, just
above the cut-off score of 12 for childhood autism [6].
ADI-R (Autism Diagnostic Interview-Revised) could not
be administered, due to his mother's limited knowledge
of the Norwegian language. When tested with Bayley Scale
of Infant Development at 4 years, his cognitive ability
score corresponded to that of 2 years. Like most autistic
children, his visual-spatial abilities were much better than
his language abilities. WPPSI-R (Wechsler Preschool and
Primary Scale of Intelligence) at 5 years demonstrated vis-
ual-spatial abilities corresponding to 3 years of age. The
verbal tests could not be administered due to lack of ver-
bal abilities. Psychometric testing concluded with moder-
ate mental retardation. This was also in accordance with
the Vineland-2 Adaptive Behavior Scale, reported by his
teacher. Motor development appeared normal when
using the Movement Assessment Battery for Children test
manual. During this examination, he was not able to fol-
low verbal instructions.
Biochemical examinations
Because mental retardation and autism sometimes can be
caused by inborn errors of metabolism [7], plasma and
urine samples from the patient were analyzed by a metab-
olite screening system [8] including gas chromatography-
mass spectrometry (GC/MS) (organic acids), amino acid
analyzer, tandem mass spectrometry (MS/MS) (purines,
pyrimidines, acylcarnitines), and capillary electrophoresis
(transferrin variants). Considerable amounts of 2-methyl-
butyryl glycine were identified in his urine. The excretion
of 2-ethylhydracrylic acid was unremarkable. The patterns
of amino acids and purines/pyrimidines were normal,
except for a slight increase in glycine. MS/MS analysis of
acylcarnitines showed increased plasma level of C5-acyl-
carnitine (1.43 micromoles/L, reference range 0.05–0.38)
and an increased C5/C3-acylcarnitines ratio of 2.83 (refer-
ence range 0.16–0.73).
Genetic analysis
DNA was extracted from blood and cultured fibroblasts
by standard methods. PCR amplification of all exons and
part of the flanking intron sequences of the human
ACADSB (SBCAD) gene were carried out by use of intron-
located primers under standard conditions in an auto-
mated thermal cycler (Thermal cycler 480, PE) [1]. The
PCR products were sequenced in both directions using a
3100-Avant genetic analyzer and a BigDye® Terminator
v1.1 Cycle Sequencing kit (Applied Biosystems).Journal of Medical Case Reports 2007, 1:98 http://www.jmedicalcasereports.com/content/1/1/98
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Sequence analysis of all exons, and part of the flanking
introns of the human SBCAD gene from patient genomic
DNA, revealed an apparent homozygosity for an A > G
mutation, which changed the +3 position of intron 3 of
the SBCAD gene (c.303+3A > G). No other changes were
observed. Sequence analysis of the mother showed heter-
ozygosity for the same c.303+3A > G mutation.
Discussion
It is well known that inborn errors of metabolism can
cause developmental delay, epilepsy and various other
neurological symptoms. The yield of metabolic examina-
tions increase with the severity of developmental delay
and the extent of associated neurological handicaps. In
routine clinical practice, metabolic, genetic, and neuroim-
aging investigations are indicated in selected children.
Abnormalities uncovered by such studies rarely dictate
significant change in the management of those patients,
but may provide important information for family mem-
bers. Novel evidence on brain mechanisms may occasion-
ally advance our understanding of the brain dysfunctions
responsible for the phenotype. The association of
SBCADD with autism may be causative or possibly a
chance association given the frequency of autism in the
general population.
Because many of these biochemical defects can be indi-
cated by analysis of organic acids in urine and MS/MS-
based analysis of acyl-carnitines in blood-spots or plasma,
we have initiated a program with metabolic screening
from autistic patients at our hospital. So far we have
screened approximately 80 individuals with autistic spec-
trum disorder since 2004. The patient in the present study
had increased urinary excretion of 2-methylbutyryl gly-
cine. He also had increased C5-carnitine levels in plasma,
which can be caused by isovaleric acidemia, antibiotics
(Pivalic) or SBCADD. Based on these biochemical find-
ings, SBCADD was suspected as the most likely condition
and the diagnosis was confirmed by identification of
homozygosity for the c.303+3A > G mutation. The
c.303+3A > G mutation causes complete skipping of exon
3 and the deleterious nature of this mutation has previ-
ously been confirmed in patient cells and also from mini-
gene studies [5]. The same mutation was identified in two
other unrelated East-African (Ethiopia and Somalia) fam-
ilies affected by SBCADD. One patient was homozygous
and another patient was predicted to be compound heter-
ozygous for the mutation [2]. The fact that the present
patient is also of East-African origin may indicate that the
c.303+3A > G mutation is relatively prevalent in this geo-
graphical area.
Several amino acids are involved in the process of neuro-
nal signalling, either as neurotransmitters, or they act as
precursors or antagonists of neurotransmitters. Distur-
bance in the metabolic pathway of these amino acids as
occurring in SBCADD, could therefore be predicted to
cause a wide range of neurological symptoms, for example
seizures, mental retardation and autism. The three amino
acids with branched side chains, leucine, isoleucine and
valine are oxidized as fuels in the brain, although their pri-
mary role is in muscle, adipose tissue, and kidney.
Our patient exhibited clinical signs of brain dysfunction
including mental retardation, abnormal behavior, and a
history of infantile seizures. We have no record of the EEG
findings from the time he was hospitalized in Somalia, so
the question regarding possible hypsarrythmia and infan-
tile spasms is unanswered. However, this epileptic syn-
drome was most likely the case, considering a typical age
of onset and description of the seizures. Infantile spasms
also occurred in the SBCADD patient reported by Madsen
[5] and epilepsy was reported in the patient described by
Gibson [2], although the seizures were described as being
focal.
Our patient exhibited developmental abnormalities com-
patible with autism, thus expanding the clinical spectrum
of this rare biochemical disorder. Developmental regres-
sion has so far not been observed in SBCADD. However,
a defect in a neighbouring enzyme step in the degradation
pathway of isoleucine, 3-hydroxy-2-methylbutyryl-CoA
dehydrogenase deficiency (OMIM 300438), was charac-
terised by progressive dystonia, seizures and blindness
[9,10].
In inherited metabolic disorders, homozygosity for a par-
ticular disease causing mutation is not always sufficient to
cause clinical symptoms. The mother of one clinical case
and the sister of another case were shown to have genetic
defects identical to their SBCADD relatives. In addition,
they excreted 2-methylbutyrylglycine in the urine. Despite
the genetic and biochemical abnormalities, these relatives
were asymptomatic [2,5].
Because SBCADD may cause accumulation of C5-carni-
tine in the blood, the enzyme defect can be detected by
MS/MS analysis of blood spots in the screening of new-
borns for metabolic disease [11]. Using this method, 8
Hmong Chinese neonates were identified to have moder-
ately elevated plasma C5-acylcarnitine levels and were
subsequently found to have 2-methylbutyryl glycinuria.
Molecular genetic analysis in 3 of the cases revealed
homozygosity for a c.1165A > G mutation, which is asso-
ciated with skipping of exon 10 of the SBCAD gene.
Except for one child who developed mild muscle hypoto-
nia, the other cases were asymptomatic. The explanation
for a mild phenotype in these individuals of Hmong Chi-
nese origin is unclear. Possibly, overlapping enzyme activ-
ity from other short branched acyl-CoA enzymes, such asJournal of Medical Case Reports 2007, 1:98 http://www.jmedicalcasereports.com/content/1/1/98
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ACAD-8, with SBCAD may be sufficient to avoid harmful
accumulation of metabolites from isoleucine metabolism
in patients with SBCADD under circumstances when they
are not metabolically challenged [1]. External factors such
as infections and metabolic stress may be necessary to trig-
ger disease symptoms in genetically predisposed individ-
uals. For example, in other acyl-CoA dehydrogenase
defects, such as MCAD and glutaryl-CoA dehydrogenase
deficiency, asymptomatic homozygous relatives of clini-
cally affected individuals have been reported [12-14].
Deficiency of SBCAD leads to accumulation of its sub-
strate, 2-methylbutyryl-CoA within the mitochondrion.
This substance is transesterified with glycine by the mito-
chondrial enzyme acyl-CoA glycine-N-acyltransferase
(glycine-N-acylase) to form 2-methylbutyryl glycine. The
discovery of SBCADD in the first reported patients, as well
as in our patient, relies on the detection of abnormal
excretion of 2-methylbutyryl glycine in the urine. The fre-
quency of SBCADD is probably underestimated because
detection and recognition of urine acylglycines is prob-
lematic. 2-ethylhydracrylic aciduria has been proposed as
a new diagnostic marker that could lead to improved
detection of SBCAD [15], but the excretion of this acid
was not remarkable in our patient. Also, a high normal
acylcarnitine profile with C5 carnitine below the cut off
value as previously described in two patients, suggests that
SBCADD may go undetected and hence be more frequent
than indicated from the limited number of reported cases
[11].
Conclusion
It is important to consider an underlying metabolic defect
in children presenting with autism, particularly when
accompanied by seizures and severe developmental delay.
The diagnosis of SBCADD in an autistic Somali patient
was established by the detection of 2-methylbutyryl gly-
cine, using GS/MS screening of the urine, and was con-
firmed by demonstrating homozygosity for c.303+3A > G
change, which may be more frequent in Somalia and Eri-
trea. We suggest that autism spectrum disorder should be
included in the phenotypic spectrum of SBCADD.
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